Company intelligence / Profile preview

Draig Therapeutics

Cardiff, Wales, United Kingdomdraigtherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Draig’s lead candidate, DT‑101, is a positive allosteric modulator of the AMPA receptor. It has demonstrated safety, tolerability, and target engagement in Phase 1 trials. The company is initiating Phase 2 studies for MDD in 2025. Two additional highly selective GABA(_A) modulators are advancing toward clinical trials by 2026. The company’s approach aims to address large unmet needs in neuropsychiatry with differentiated small molecules targeting core neurotransmitter systems.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

DT-101

2 more assets in the full pipeline.

Request access →

Partnerships

Cardiff University / Medicines Discovery InstituteSV Health InvestorsICG Life Sciences

Beyond the preview

Go deeper on Draig Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Draig Therapeutics.

Explore the full profile